Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.74 USD
-0.01 (-1.79%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $0.74 0.00 (0.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CUE 0.74 -0.01(-1.79%)
Will CUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CUE
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
CUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
Other News for CUE
12 Health Care Stocks Moving In Wednesday's Intraday Session
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing ...
CUE-101 Shows Promising Phase 2 Results for Cue Biopharma (CUE) | CUE Stock News
Cue Biopharma provides clinical update on CUE-101, saw ORR of 50%
12 Health Care Stocks Moving In Wednesday's After-Market Session